Identification | Back Directory | [Name]
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine | [CAS]
428854-24-4 | [Synonyms]
riociguat Intermediates Riociguat Triamino Impurity N-Desmethyl-N-desmethylcarbamoly Riociguat 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimid... 2{1[(2fluorophenyl)Methyl]1Hpyrazolo[3,4 b]pyridin3yl}pyriMidine4,5,6triaMine 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine 4,5,6-Pyrimidinetriamine, 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]- Riociguat Impurity 21/2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6-triamine | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C17H15FN8 | [MDL Number]
MFCD22741544 | [MOL File]
428854-24-4.mol | [Molecular Weight]
350.353 |
Chemical Properties | Back Directory | [Melting point ]
>212°C (dec.) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO (Slightly) | [form ]
Solid | [color ]
Dark Yellow |
Hazard Information | Back Directory | [Uses]
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine is a metabolite of stimulators of soluble guanylate cyclase for the treatment of pulmonary hypertension. | [Synthesis]
General procedure for the synthesis of 2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6-triamine from the compound (CAS: 370879-49-5): to a 100 mL four-necked flask were added DMF (30 mL), LA-1 (5.0 g, 0.012 mol, 1.0 eq.), activated carbon ( 0.5 g) and FeCl3-6H2O (0.8 g, 0.003 mol, 0.25 equiv). After stirring and mixing, the temperature of the reaction system was raised to 60 °C and 80% hydrazine hydrate (15.0 g, 0.238 mol, 10.0 eq.) was slowly added dropwise. After dropwise addition, the reaction was continued at 60 °C for 20 to 24 hours. Upon completion of the reaction, filtration was performed to remove the activated carbon and the filter cake was washed with 25 mL of DMF. The combined filtrates were rotary evaporated at 85 °C to remove the solvent. To the evaporated concentrate was added 25 mL of methanol followed by the slow dropwise addition of 25 mL of water in an ice bath. After completion of the dropwise addition, stirring was continued under an ice bath for 1 hour, followed by diafiltration. The filter cake was dried at 50 °C for 16 h to give LA-2 as a khaki colored solid in a yield of 3.4 g (yield: 86.4%, liquid phase purity 98.1%, melting point 244.4-245.8 °C). | [References]
[1] Patent: CN107118211, 2017, A. Location in patent: Paragraph 0076; 0077; 0078; 0079; 0080 [2] Patent: CN105461715, 2016, A. Location in patent: Paragraph 0020 [3] Bioorganic and medicinal chemistry, 2002, vol. 10, # 6, p. 1711 - 1717 [4] Patent: WO2017/25981, 2017, A1. Location in patent: Page/Page column 34; 35 [5] Journal of Medicinal Chemistry, 2017, vol. 60, # 12, p. 5146 - 5161 |
|
|